Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
PARIS, September 10 /PRNewswire-FirstCall/ --
- Abstracts 186 and 1003
Sanofi-aventis announced today that results from two studies, GINGER
and LACE, presented at the 44th annual meeting of the European Association
for the Study of Diabetes (EASD) demonstrated that a basal-bolus insulin
Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
Data from five pivotal phase 3 studies presented at the American Diabetes Association 68th Scientific Sessions
SAN FRANCISCO, June 7 /PRNewswire/ -- Results from five pivotal phase 3
studies of alogliptin were announced today at the American Diabetes
Association (ADA) 68th Scie...
Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Single Molecule with Dual Mechanism May Offer Novel Approach to Blood Pressure Management
NEW ORLEANS, May 16 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq:
PCOP), an innovator in the discovery and development of novel small
molecule therapeutics, announced today tha...
Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
Results of SHEPHERD Phase III Open Label Trial Published in Online Edition of the Journal Blood
CHESHIRE, Conn., Dec. 4 /PRNewswire-FirstCall/ -- Soliris(R)
(eculizumab) therapy reduced hemolysis and improved fatigue, overall
quality of life and anemia in a diverse popu...
Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
- Early study data from the two lowest dose groups show dose-dependent PSA declines to date in all patients - - Conference call to be held today at 8:30 A.M. Eastern time -
SAN FRANCISCO, Nov. 5 /PRNewswire-FirstCall/ -- Medivation, Inc.
(Nasdaq: MDVN ) today announced th...
DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
SOMERSET, N.J., Sept. 25 /PRNewswire-FirstCall/ -- DOV Pharmaceutical,
Inc. ("DOV", or the "Company") (OTCBB and Pink Sheets: DOVP) announced
today additional Phase Ib results for DOV 21,947, its lead triple reuptake
inhibitor ("TRIP") for the treatment of depression and obesity. A
Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
MIAMI LAKES, Fla., Sept. 4 /PRNewswire/ -- In an extensive analysis of
clinical trials known as a meta-analysis, the CYPHER(R) Sirolimus-eluting
Coronary Stent was associated with significantly lower risks of blood clots
and the need for reintervention compared to the Taxus Stent out to 30
Lipitor Provides Unprecedented Cardiovascular Risk Reductions in
Diabetes Patients with Metabolic Syndrome and in Stroke Patients
NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Pfizer announced today
that Lipitor(R) (atorvastatin calcium) Tablets 10 mg provided a
significant 61 percent reduction in stroke in patients with type 2
diabetes and metabolic syndrome but without heart disease. In a
separate study, patients who had suf...
Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage
2 Patients Compared With Amlodipine + Benazepril
Comparison of BENICAR HCT 40/12.5 and 40/25 mg/day and Amlodipine +
Benazepril 5/20 and 10/20 mg/day Presented at American Society of
Hypertension Twenty-Second Annual Scientific Meeting
PARSIPPANY, N.J., May 21, 2007 /PRNewswire/ -- New data
presented today at the American Society of Hypertension...
Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing
Sustained Safety and Significant Reductions in Repeat Procedures
BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Medtronic
(NYSE:MDT) today presented new long-term data from the ENDEAVOR
clinical trial program reinforcing the existing safety and efficacy
profile of the Endeavor(R) drug-eluting coronary stent system.
Four-year results from the 100-patient first...
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B
Showed Significant Reductions in Disease Activity in Patients with
Active Systemic Lupus Erythematosus
-LymphoStat-B(R) significantly reduced signs and symptoms of SLE
disease at 52 Weeks and demonstrated durable clinical and
biological activity at 76 weeks-
ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- Human
Genome Sciences, Inc. today announced the presentation of Phase 2
trial data dem...
DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of
Improved Glycemic Control and Significant Reductions of
LDL-Cholesterol and C-Reactive Protein
Top Line Data for the Treatment of Type 2 Diabetes Presented at the
67th Annual Scientific Sessions of American Diabetes Association
SAN FRANCISCO, June 25, 2007 /PRNewswire/ -- DiObex, Inc., a
privately-held biopharmaceutical company focused on the development
of therapeutics to treat metabolic d...
A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to
Sustained Reductions in Blood Glucose Levels for 6 Months
Post-treatment in Type 2 Diabetes Patients
Final Results from Exploratory Phase IIa Clinical Trial in Type 2
Diabetes Patients Announced
TORONTO, June 28, 2007 /PRNewswire-FirstCall/ - Transition
Therapeutics Inc. ("Transition") , today announces the results from
its exploratory Phase IIa clinical trial indicating that 4-weeks of
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
N 73 146
--- --- ---
N % N %
--------------- --- --- --- ---
# Had a Dose R...
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
...f Tekturna and HCTZ offered greater blood pressure reductions
than either drug alone.
"Up to 85% of pa...orothiazide 12.5 mg to 25 mg alone. Blood pressure reductions
with the combinations were greater than the reductions
with the monotherapies. The safety and efficacy of...
Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
...with no response in one patient in the 25 mg cohort. Significant viral load reductions
were observed in the three higher dose cohorts (50, 75 and 100 mg/day). Pos...t no evidence of drug accumulation. The table below summarizes mean HCV RNA reductions
observed in this study per cohort:
Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study
.... The study, published in The Journal of Arthroplasty , found significant reductions
in acetabular bone loss adjacent to the Trabecular Metal device compared ...nt products; product liability and intellectual property litigation losses; reductions
in reimbursement levels from third-party payors and cost-containment effort...
Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
...ver and cardiovascular disease as well as diabetes. Preclinical animal studies with the Company's compounds or its active metabolite have demonstrated reductions
in blood pressure, triglycerides, cholesterol levels, C-reactive protein, and fasting blood glucose levels. Enzyme levels indicative of liver damage, ...
Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
...ffectively managed," he added.
Safety Results Tables
(N) Placebo (153) 150 mg qd (152) 100 mg bid (152)
N % N % N %
# Had a Dose
Reduction 6 4% 21 14% 21 14%
AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
...e pain following major abdominal surgery reported statistically significant reductions
in pain intensity over the 12-hour study period.
This multicenter, dou... ARX-01 10 mcg and 15 mcg treatment groups showed statistically significant reductions
in pain intensity over the study period (p<0.001 for each) based on the ...
King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
... crushed or chewed, the naltrexone would be released, mitigating the euphoric effect of the morphine. The clinical significance of the degree of these reductions
has not been established and there is no evidence that the naltrexone in EMBEDA(TM) reduces the abuse liability of EMBEDA(TM).
About King Pharma...
New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%
...te to 24 months versus a 50% survival rate for the control group rats that were not fed prebiotics. Additionally, the "prebiotic" rats showed material reductions
in cholesterol and body weight versus the control group.
Significantly, the prebiotic used in the study was oligofructose enriched inulin, a ...
HCPC Calls for Greater Healthcare Savings Through Improved Adherence to Prescription Drug Regimens
...r drugs in blister packs with compliance-prompting features refilled their prescriptions in a much for timely manner and also achieved markedly better reductions
in their blood pressure readings.
The OSU study is just one example of research which points to the role that unit dose formats can play in im...
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
...dy biopsies using the improved methodology demonstrated that all of the evaluable baseline samples had detectable interstitial capillary GL-3 and that reductions
were observed in 8 of the 9 responders.
According to Laura Barisoni, MD, Assistant Professor in Pathology and Medicine, Director, Nephropathology...
Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia
...d Forward analysis.
Additional Data Highlights
Patients treated with sodium oxybate 4.5 g/night and 6g/night showed significant reductions
in fatigue as early as Week 1 after dosing compared with placebo as measured by the Fatigue VAS (p<0.001). These differences were maintained throu...
Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions
...ty in multiple animal models including non-human primates. Collectively, the data suggest that ISIS-SGLT2Rx could result in sustained and significant reductions
in blood glucose levels in diabetic patients and could be used as an infrequent injectable drug to help control blood sugar. This year, we have initi...
Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
...(32% ORR), DLBCL (30% ORR) and small lymphocytic lymphoma (18% ORR)(1).
Patients received everolimus 10 mg daily and were evaluated monthly. Dose reductions
to 5 mg daily and 5 mg every other day were permitted. Response was assessed after two cycles of treatment and periodically thereafter. Patients recei...
Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
...ection for 30 weeks, followed by 74 weeks of treatment with exenatide once weekly for all patients during an open-ended assessment period. Significant reductions
in A1C of 1.7 percent and fasting plasma glucose (FPG) of 40 mg/dL were maintained after two years of treatment. Sixty-five percent of patients achiev...
Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride: Oral 162
...ide, taken as monotherapy, leads to statistically significant and sustained reductions
in blood sugar and weight after two years of treatment.
In the study,... is consistent with its other long-term clinical benefits such as continued reductions
in fasting blood sugar and weight," said Dr. Alan Garber, Baylor College o...
Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight
...g blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.
In the study, dose-dependent reductions
in A1C - a measure of how well blood sugar is being controlled over time - with albiglutide 30 mg weekly, 50 mg biweekly, and 100 mg monthly were 0.9%...
Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients
..., 1-hour PPG, 2-hour PPG and FPG following a standard meal challenge, and body weight. Adverse events were monitored to compare safety profiles.
in A1C were comparable in both treatment groups with no significant differences in LAA doses in either group. FPG levels (-35.5 +/- 3.3 vs. -20.6 +/-...
New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar
"By combining basal insulin Lantus(R) plus Apidra(R) mealtime insulin at one, two or three meals throughout the day, we observed A1C reductions
with many patients achieving the target A1C of less than 7 percent," stated Mayer Davidson, M.D., Professor of Medicine, UCLA School of Medicine, Los ...
Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
...uded changes in fasting serum glucose, solid mixed meal glucose excursion and body weight.
For all doses in this study, statistically significant reductions
in all metabolic measures were observed. Both 1 mg and 2 mg doses of LY2189265 were significantly different from placebo, but no significant differen...
Boehringer Ingelheim Unveils Diabetes Pipeline
...linically relevant and statistically significant reductions
in HbA1c, a measure of blood sugar, when given as ... clinically relevant and statistically significant reductions
in HbA1c and fasting blood sugar or fasting plasma...%):(1)
Statistically significant reductions
in mean HbA1c levels with linagliptin 5 mg and 10 ...
PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
...g to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions
or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparV...
Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
...ntly demonstrated anti-tumor activity in both chemotherapy-naive and post-chemotherapy CRPC patients across dose levels and endpoints, as evaluated by reductions
in prostate specific antigen (PSA) levels, radiographic findings and circulating tumor cell (CTC) counts.
New findings include the median time to...
Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
...associated with the approved proteasome inhibitor, bortezomib. Exacerbation of pre-existing peripheral neuropathy was rare and did not result in dose reductions
or discontinuation of therapy. Overall, adverse events did not limit treatment duration, even among patients with several co-morbidities.
Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
...Cerebral Edema Demonstrated Clinically Significant reductions
in Steroid Usage Compared to Placebo
New Pr... well tolerated and enabled clinically significant reductions
in corticosteroid use in patients with cerebral ed... of XERECEPT(R) leads to statistically significant reductions
in steroid-related adverse events of myopathy (mus...
Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
... orally in daily doses is associated with clinical benefit as determined by reductions
in tumor volume, reductions
in tumor markers, and improvement in cancer-related symptoms. These benefit...
New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
... patients enrolled in part 2 and was the most significant grade 3 or 4 adverse event, occurring in 25 percent of patients. Fourteen patients had dose reductions
and one patient withdrew from the study due to an adverse event.
"Emerging clinical data continue to suggest that neratinib, in combination wit...